GLP-1 Medication Costs in 2026: A Comparative Pricing Guide

In late 2024, Eli Lilly opened a direct-to-consumer channel for Zepbound vials at prices that undercut the pen list price by roughly half. By early 2026, both Lilly and Novo Nordisk had expanded those programmes, and the pricing landscape for GLP-1 medications had shifted in ways that would have looked unlikely two years earlier.

The headline numbers still cause sticker shock. List prices for the major branded products remain above $1,000 per month for cash payers without any discount programme. But the actual price most uninsured patients pay in 2026 is rarely the list price. Between manufacturer direct programmes, savings cards with eligibility criteria, telehealth bundled pricing, and the still-contested market for compounded versions, the practical cost ranges widely.

The list prices that almost nobody actually pays

The wholesale acquisition cost — what pharmacies pay manufacturers before any rebates or discounts — anchors a system most patients never interact with directly. As of early 2026, Wegovy's list price sits at approximately $1,349 for a 28-day supply, Zepbound's pens at approximately $1,086, Ozempic at approximately $968, and Mounjaro at approximately $1,069. These numbers appear on insurance explanation-of-benefits forms and in policy debates more than they appear on patient receipts.

What patients without insurance actually face is a layered pricing landscape with several distinct tiers. The list price is the ceiling. The floor varies considerably depending on which programmes and channels a patient is willing to use.

Manufacturer direct-to-consumer programmes

Eli Lilly's LillyDirect Self Pay programme, launched in August 2024 and expanded through 2025, offers Zepbound single-dose vials at prices that started at $399 for the 2.5 mg dose and $549 for the 5 mg dose. By 2026, additional doses have been added to the vial programme, with the 7.5 mg and 10 mg vials priced in a similar self-pay tier. The vials require self-administration with a separate syringe rather than the auto-injector pen, which is the trade-off for the lower price.

Novo Nordisk's NovoCare Pharmacy programme, launched in early 2025, took a similar approach for Wegovy. Self-paying patients can obtain Wegovy at prices that opened around $499 per month for all dose strengths through the direct channel, contingent on a valid prescription. The pricing has stayed in roughly that range through 2026, with periodic promotional adjustments.

The economics of these programmes reflect a calculated trade by both manufacturers. By bypassing the traditional pharmacy benefit manager chain — which typically captures a substantial portion of GLP-1 revenue through rebates and fees — the manufacturers can offer cash prices that look low compared to list while still capturing reasonable margins. The programmes also expand the eligible market beyond patients whose insurance covers the medications.

Savings card programmes

For patients with commercial insurance that excludes GLP-1 coverage, manufacturer savings cards remain relevant. The Wegovy savings card historically reduced out-of-pocket cost to as little as $0 for the first three fills and capped subsequent out-of-pocket at $225 per month for eligible patients with commercial insurance. The Zepbound savings card offered comparable terms, with maximum savings of $469 per month for commercially insured patients without coverage.

These cards typically exclude patients on Medicare, Medicaid, or other government programmes — a restriction set by federal anti-kickback rules rather than manufacturer preference. The exclusion is part of why direct-to-consumer programmes have grown: they fill the gap left by savings cards' eligibility limits.

Compounded semaglutide and tirzepatide

The compounded version of these medications occupied an unusual regulatory space during the 2023–2024 FDA shortage listings. While semaglutide and tirzepatide were officially in shortage, 503A and 503B compounding pharmacies could legally produce compounded versions for individual patients. Prices ranged from roughly $150 to $400 per month, substantially below branded products.

The regulatory landscape changed once the FDA removed both molecules from its shortage list — tirzepatide in late 2024 after resolution, semaglutide in early 2025. After the formal end of shortage, the legal grounds for routine compounding narrowed significantly. The FDA issued guidance restricting compounding of these molecules outside specific clinical circumstances, and several states tightened pharmacy enforcement.

As of 2026, compounded versions remain available through some telehealth channels under specific clinical justifications — patient allergies to inactive ingredients, dose strengths not commercially available, and similar exceptions. The pricing is still lower than branded products, often in the $200–$350 range, but the legal and quality landscape has narrowed compared to the 2023–2024 peak. Patients considering compounded options should ask the prescribing service which compounding pharmacy is used, whether it is 503A (state-licensed) or 503B (FDA-registered outsourcing facility), and what testing the active pharmaceutical ingredient has undergone.

Telehealth bundled pricing

Several telehealth services bundle prescription, consultation, and medication into a single monthly subscription. The pricing varies by service and dose, but typical bundled offerings range from approximately $200 per month at the lower end (often compounded options) to $600+ per month for branded products through telehealth-affiliated pharmacies.

The bundled model can be the simplest path to access for patients without insurance, since it eliminates the separate workflows of finding a prescriber, getting a prescription filled, and managing prior authorization. The trade-off is that the bundled price is rarely the lowest possible price for the medication itself — patients who are willing to manage the workflow themselves can often do better through manufacturer direct programmes.

For an overview of how telehealth services compare on access, pricing, and clinical quality, our review of telehealth GLP-1 prescription services covers the landscape in more detail.

The international price comparison

The U.S. pricing context looks unusual against the international landscape. In Germany, semaglutide for diabetes is priced at roughly €100 per month. In the UK, NHS prescribing of Wegovy through specialist services costs the NHS around £73 per month. Australian PBS-subsidised pricing puts Ozempic at AUD $30 for diabetes patients. The pricing differential between the U.S. and other developed markets has narrowed slightly since the introduction of manufacturer direct programmes, but the gap remains substantial.

For uninsured U.S. patients, this comparison is mostly academic — international pharmacies cannot legally ship these medications to U.S. addresses, and the FDA actively discourages importation. The international pricing data does, however, inform ongoing U.S. policy debates about Medicare price negotiation, which began including semaglutide in its 2026 negotiation list.

The Medicare situation in 2026

Standard Medicare Part D continues to exclude coverage for weight-loss medications under a 2003 statutory provision. The Centers for Medicare and Medicaid Services has issued guidance allowing coverage when semaglutide is prescribed for cardiovascular risk reduction (the FDA-approved indication added in 2024 based on the SELECT trial) — a workaround that brings some Medicare patients into coverage if they meet the cardiovascular criteria. Pure obesity indications remain excluded.

The 2026 Medicare drug price negotiation list includes semaglutide. Final negotiated prices take effect in 2027, but the negotiation itself signals where federal pricing pressure is heading. Patients currently on Medicare without cardiovascular indications generally pay full cash prices or use the manufacturer direct programmes.

What this means for an uninsured patient in 2026

The practical question for most uninsured patients is which of three paths to follow.

Manufacturer direct programmes (LillyDirect for Zepbound, NovoCare for Wegovy) offer the most predictable pricing for branded medications, currently in the $399–$549 range depending on dose. The trade-off is self-administered vials rather than pens for Zepbound, and the requirement to manage prescription and pharmacy logistics directly.

Telehealth bundled subscriptions trade somewhat higher pricing for workflow simplicity. They handle prescription, consultation, and pharmacy in one channel. They are the right fit for patients who value convenience over absolute lowest price.

Compounded options remain the lowest-priced path where they are available, typically through telehealth services. The narrowed regulatory landscape after the shortage resolution means these are no longer the unrestricted market they were in 2023, and patients should verify the clinical justification, compounding pharmacy credentials, and product testing.

For patients who do have insurance but are facing coverage denials, the procedural path is a separate question — covered in detail in our guides on getting GLP-1 covered by insurance and prior authorization tips. The cash pricing landscape described here is the fallback when those routes don't work.

Key takeaways

• List prices for branded GLP-1 medications remain above $1,000 per month in 2026, but most uninsured patients pay considerably less through alternative channels.
• LillyDirect Self Pay offers Zepbound vials starting at $399 for 2.5 mg and $549 for 5 mg; NovoCare Pharmacy offers Wegovy at approximately $499 per month for self-paying patients.
• Manufacturer savings cards remain useful for commercially insured patients without GLP-1 coverage, but exclude Medicare and Medicaid recipients.
• Compounded semaglutide and tirzepatide are no longer freely available after the FDA removed both from shortage status; remaining access is limited to specific clinical justifications at prices typically $200–$350 per month.
• Telehealth bundled subscriptions range from approximately $200 to $600+ per month, trading higher pricing for workflow simplicity.
• Medicare continues to exclude weight-loss indications but covers semaglutide for cardiovascular risk reduction in eligible patients; semaglutide is on the 2026 Medicare drug price negotiation list.